



Please type a sign (+) inside this box

 $+_{PTO/SB/05}$ (08-00)

Approved for use through 10/31/2002 OMB 0651-0032
Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

	TTTTTTTV	Attorney Docket No. PT020P1										
	UTILITY DATENT ADDITON	First Inventor Ruben et al.										
	PATENT APPLICATION TRANSMITTAL	Title Protein Tyrosine Kinase Receptor Polynucleotides, Poypeptides, and Antibodies										
J	(Only for new nonprovisional applications under 37 CFR ' 1.53(b))	Express Mail Label No.										
	APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents	ASSISTANT Commissioner for Patents Box Patent Application Washington, DC 20231										
	1. Ee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing)	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)										
	2. Applicant claims small entity status. See 37 CFR 1.27.	8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF)										
	3. Specification [Total Pages 293] (preferred arrangement set forth below) Page in the file Invention	b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or										
	- Descriptive title of the Invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Company of the Co	ii. ⊠ paper Statements verifying identity of above copies										
	 Reference to sequence listing, a table, or a computer program listing appendix Background of the Invention 	ACCOMPANYING APPLICATION PARTS										
WE W	 Brief Summary of the Invention Brief Description of the Drawings (if filed) 	9. Assignment Papers (cover sheet and document(s))										
The draft from Just for the	 Detailed Description Claim(s) Abstract of the Disclosure 	10. 37 CFR 3.73(b) Statement Power of Attorney										
The state of	4. Drawing(s) (35 U.S.C. 113) [Total Sheets]	11. English Translation Document (if applicable)										
Wall Harr	5. Unexecuted Oath or Declaration [Total Pages 2]	12. Information Disclosure Statement/ Form PTO/SB/08										
# 111	a. Newly executed (original or copy)b. Copy from a prior application (37 CFR 1.63(d))	Copies of Citations										
offine of	(for continuation/divisional with Box 17 completed)	13. Preliminary Amendment										
The first first that the	 i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR ' ' 1 63(d)(2) and 1.33(b) 	14. Return Receipt Postcard (MPEP 503) (should be specifically itemized)										
undin	6. Application Data Sheet. See 37 CFR 1.76.	15. Certified copy of Priority Document(s) (If foreign priority is claimed)										
		16.										
	17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:											
	Continuation Divisional Continuation-in-Part (CIP) of prior application No: PCT/US00/28066 filed October 12, 2000 which claims benefit under 35 U.S.C. § 119(e) based on U.S. Provisional Applications Nos. 60/159,542, filed October 15, 1999; 60/165,914 filed November 17, 1999, and 60/189,027 filed March 14, 2000 Prior application information: Examiner Group/Art Unit: For CONTINUATION OR DIVISIONAL APPS only The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the eccompanying continuation or divisional application and is hereby incorporated by reference. The incorporation gan only be relied upon when a portion has been inadvertently omitted from the submitted application parts.											
į	18. CORRESPONDENCE ADDRESS											
	Customer Number or Bar Code Label 22195 or Correspondence address below											
Ī	NAME											
-	ADDRESS											
f	CITY STATE	ZIP CODE										
ł	COUNTRY TELEPHONE											
į	NAME (Print/Type) Kenley K. Hoover	Registration No. (Attorney/Agent) 40,302										
SIGNATURE Date April 18,2												

PTO/SB/17 (09-00)

Approved for use through 10/31/2002 OMB 0651-0032

Patent and Trademark Office U S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2001							Complete if Known							
IOF F Y 2001 Patent fees are subject to annual revision.														
	Fute	mi jees are s	suvjeci i	o annuai re	vision.		Application Number					Unassigned		
							Filing Date					April 18, 2001		
							First Named Inventor					Ruben et al.		
								er Name				- Attabell Ct		
								Art Unit				·		
Total an	ount of	payment			1 6	5)746.00	Attorney Docket Number					PT020P	1	
METHOD OF PAYMENT (CHECK ONE)								FEE CALCULATION (CONTINUED) 3. ADDITIONAL FEES						
Me The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to								3. ADDITIONAL FEES Large Entity Small Entity						
Deposit	Accou		0	8-3425			Fee Code	Fee	Fee	Fee	Fee		Fee Paid	
Number Deposit Account Human Genome Sciences, Inc. Name								(\$) 130	Code 205	(\$) 65	Description Surcharge - late provisional fil	ling fee or cover		
1444	iic						127	50	227	25	Surcharge - late provisional filing fee or cover sheet			
⊠ Cha	arge Ar	y Addition	al Fee	Required			139	130	139	130	Non-English specification			
Un	der 37	CFR §§ 1.1	16 and	1.17			147	2,520	147	2,520	For filing a request for ex part	For filing a request for ex parte reexamination		
							112	920	112	920		Requesting publication of SIR prior to Examiner		
Applicant claims small entity status								1,840	113	1,840	action Requesting publication of SIR after Examiner			
See 37 CFR 1.27								110	215	55	action Extension for reply within firs	tion ttension for reply within first month		
								390	216	195	• •	extension for reply within second month		
2. D Payment Enclosed								890	217	445	- ·	Extension for reply within third month		
. 28		Credit Card		-			118	1,390	218	695	Extension for reply within fou	Extension for reply within fourth month		
* Charge any deficiencies or credit any overpayments in the fees or fee calculations of Parts 1, 2 and 3 below to Deposit Account No. 08-3425							128	1,890	228	945	Extension for reply within fift	Extension for reply within fifth month		
Caloughio	ns of Farts	1, 2 and 3 below	v to Depos	n Account No.	08-3425		119	310	219	155	Notice of Appeal			
FEE CALCULATION								310	220	155	Filing a brief in support of an	anneal		
1. BASI	FILIN						120 121	270	221	135	Request for oral hearing			
Large	2°2°3					138	1,510	138	1,510	Petition to institute a public us	e proceeding			
Fee Fee Fee Description Paid														
101					\$710 00	140	110	240	55	Petition to revive -unavoidable		····		
106	a.a. 6			Design filing fee		141	1,240	241	620	Petition to revive - unintentior				
107 490 207		245	Plant filing			142	1,240	242	620	Utility issue fee (or reissue)				
108= 114	108 710 208 355 Reissue filing fee 114 75 Provisional filing fee				143 144	440 600	243 244	220 300	Design issue fee	Design issue fee				
2000	150	214	73	1 IOVISIONAL	ming tee		122	130	122	130	Petitions to the Commissioner			
Subtotal (1) \$710.00					123	50	123	50		titions related to provisional applications				
- E							126	240	126	240	Submission of Information Di-			
2. EXTR	CLAIM	FEES					581	40	481	40	Recording each patent assignment (times number of properties)	nent per property		
Fee Fee				146	710	246	355	Filing a submission after final	rejection	i				
IJ.				Extra	from	Paid					(37 CFR 1.129(a))			
Total clai	ms	22	- 20**	2	below	\$36.00	149	710	249	355	For each additional invention CFR 1.129(b))	to be exammed (37		
Indep.claims 2 - 3** 0 \$0.00					179	710	279	355		for Continued Examination (RCE)				
Multiple Dependent					\$	169	190	169	900	Request for expedited examina application	ation of a design			
<u> </u>				 			i	e (specify).						
Large Fee	Entity Fee	Small Fee	Entity Fee	Fee Description	on		Other fee	(specify):						
Code	(\$)	Code	(\$)	Cacripin										
• • • •							*Reduced by Basic Filing Fee Paid							
103 18 203 9 Claims in excess of 20 102 80 202 40 Independent claims in excess of 3														
104	270	204	135	Mutliple d	lependent o	laim								
108 80 209 40 **Reissue independent claims														
over original patent 110 18 210 9 **Reissue claims in excess of 20 and over original patent						Subtotal (3)						\$		
and over original patelli														
Subtotal (2) (\$)746.00														
Submit	ted By											C	omplete (if applicable)	
Name (Print/Type) Kenley K, Hoover							Registration No.: 40,302 Telephone						301-309-8504	
Signatu		1/	11	the								Date Apri		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of: Ruben et al.

Application Serial No.: Not assigned Art Unit: Not assigned

Filed: Concurrently herewith Examiner: Not assigned

For: Protein Tyrosine Kinase Receptor

Polynucleotides, Polypeptides, and Antibodies Attorney Docket No.: PT020P1

STATEMENT UNDER 37 C.F.R. 1.821(f)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants hereby certify that the hard copy of the sequence listing being filed concurrently herewith and the enclosed computer-readable form of such sequence listing are identical.

Respectfully submitted,

Attorney for Applicants

Human Genome Sciences, Inc.

Reg. No. 40,302

9410 Key West Avenue Rockville, Maryland 20850 Telephone: (301) 610-5771

KKH/RL/KC/ur